PUBLISHER: The Business Research Company | PRODUCT CODE: 1751003
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751003
Galantamine hydrobromide is a pharmaceutical compound used to treat mild to moderate Alzheimer's disease and other memory-related conditions. As an acetylcholinesterase inhibitor, it works by increasing acetylcholine levels in the brain, which improves nerve signal transmission and cognitive function. Galantamine hydrobromide helps slow cognitive decline and enhances memory, attention, and overall mental function in patients with neurodegenerative disorders.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main galantamine hydrobromide products include tablets, capsules, and oral solutions. Tablets are solid forms of medicine taken orally, where they dissolve in the digestive system to release the active ingredients. Galantamine hydrobromide is used for treating Alzheimer's disease, enhancing cognitive function, and other purposes by various end-users, including hospitals, research institutions, homecare settings, and long-term care facilities.
The galantamine hydrobromide market research report is one of a series of new reports from The Business Research Company that provides galantamine hydrobromide market statistics, including galantamine hydrobromide industry global market size, regional shares, competitors with a galantamine hydrobromide market share, detailed galantamine hydrobromide market segments, market trends and opportunities, and any further data you may need to thrive in the galantamine hydrobromide industry. This galantamine hydrobromide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The galantamine hydrobromide market size has grown rapidly in recent years. It will grow from $0.67 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth observed during the historic period can be attributed to rising investments, a growing elderly population, an increasing diagnosis rate, heightened awareness of neurodegenerative illnesses, and a rise in life expectancy.
The galantamine hydrobromide market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth projected during the forecast period can be attributed to an increase in clinical trials, a growing emphasis on early diagnosis, a rising incidence of Alzheimer's disease, expanded research funding and drug development efforts targeting Alzheimer's, and a strengthened focus on research and development. Key trends during this period include collaborations between pharmaceutical companies and research institutions, advancements in treatment options, the expansion of indications for galantamine hydrobromide through ongoing clinical trials, the rise of personalized medicine, and progress in biotechnology and pharmaceutical research.
The growing prevalence of Alzheimer's disease is expected to drive the expansion of the galantamine hydrobromide market over the forecast period. Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, often impairing the ability to carry out everyday activities. The incidence of Alzheimer's is rising due to the aging global population, as the likelihood of developing the disease increases significantly with age due to accumulated brain changes and genetic predisposition. Galantamine hydrobromide is used to manage Alzheimer's symptoms by increasing acetylcholine levels through inhibition of its breakdown, thereby helping to slow cognitive decline and enhance memory in patients with reduced neurotransmitter function. For instance, in August 2024, the Centers for Disease Control and Prevention (CDC) reported that the number of individuals living with Alzheimer's in the U.S. is expected to rise from 6.9 million to nearly 14 million by 2060. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the galantamine hydrobromide market.
Leading companies in the galantamine hydrobromide market are developing next-generation acetylcholinesterase inhibitors (AChEIs) to improve treatment outcomes, reduce side effects, and promote better patient adherence. These advanced AChEIs aim to enhance cognitive performance in neurodegenerative conditions by improving bioavailability while minimizing adverse effects. For example, in July 2024, Alpha Cognition Inc., a Canada-based biopharmaceutical company, received U.S. FDA approval for ALPHA-1062 (Zunveyl), a prodrug version of galantamine for mild to moderate Alzheimer's disease. ALPHA-1062 features improved safety and bioavailability compared to traditional formulations. Unlike standard galantamine, it is absorbed in the small intestine as an inert substance, avoiding early interaction with acetylcholinesterase in the gastrointestinal system. The addition of a benzyl ester helps reduce local neuronal overstimulation, lessens gastrointestinal side effects, and enhances bioavailability. Once metabolized in the liver, ALPHA-1062 becomes active and delivers galantamine efficiently to the brain through the bloodstream.
In April 2024, Essential Pharma Group Limited, a UK-based specialty pharmaceutical company, acquired the oral capsule formulation of Reminyl (galantamine hydrobromide) from Janssen Pharmaceutica NV for an undisclosed amount. This acquisition ensures the continued availability of and access to galantamine hydrobromide treatment for Alzheimer's patients. Janssen Pharmaceutica, a Belgium-based pharmaceutical company, is known for developing therapies across several fields including neurology, infectious diseases, immunology, oncology, and cardiology.
Major players in the galantamine hydrobromide market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ajinomoto Co. Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Jubilant Pharmova Limited, Cohance Lifesciences Limited, Indena S.p.A., ScinoPharm Taiwan Ltd., Estechpharma Co. Ltd., Nortec Quimica S.A., Metrochem API Private Limited, Sanochemia Pharmazeutika AG, Pellets Pharma Limited, Midas Pharma GmbH, Jubilant Generics, Capital Farma, Wuhan Shiji Pharmaceutical Co. Ltd., Credo Life Sciences Pvt. Ltd.
North America was the largest region in the galantamine hydrobromide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in galantamine hydrobromide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the galantamine hydrobromide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The galantamine hydrobromide market consists of sales of extended-release capsules, injectable solutions, transdermal patches, sublingual drops, and powder for compounding. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Galantamine Hydrobromide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on galantamine hydrobromide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for galantamine hydrobromide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The galantamine hydrobromide market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.